Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: rrufff who wrote (21151)	6/7/2004 9:20:20 AM
From: rrufff	Respond to of 120415

CTE - 3.92 down almost 1/2 from its high, used to be a favorite here. Has so many things in the pipeline. Read the filings. One of the best opportunities in biomedical devices. CardioTech International's Wholly-Owned Subsidiary DermaPhylyx Awarded 'Medicare Participating Provider' Status For Wound Dressing Technologies PR Newswire - June 07, 2004 08:30 WILMINGTON, Mass., Jun 7, 2004 /PRNewswire-FirstCall via COMTEX/ -- CardioTech International, Inc. (Amex: CTE) today announced that its wholly-owned DermaPhylyx International, Inc. subsidiary has been accepted as a Medicare supplier of Durable Medical Equipment, Orthotics, Prosthetics and Supplier (DMEPOS), also known as a Medicare Participating Provider (MPP). Under the status, Medicare patients who order HydroMed or AlgiMed can receive wound dressings at no out-pocket expenses to them, since DermaPhylyx will now be eligible for Medicare reimbursement. Medicare patients may now order their wound dressing needs by telephone, email or in person at DermaPhylyx International, Inc. 229 Andover St. Wilmington, MA 01887. Dr. Michael Szycher, CEO and Chairman of CardioTech International, stated: "We are very pleased to announce that we have been awarded the coveted Medicare Participating Provider Status. I believe this will contribute significantly in advancing the sales and distribution of our wound dressings." DermaPhylyx is marketing two advanced, moist wound healing products: HydroMed and AlgiMed. HydroMed(TM) is a non-adhering, moisture donating hydrogel sheet containing 90% water and 10% hydrophilic polymer. It is intended for use on lightly exudating wounds. HydroMed(TM) is intended for use in the management of chronic wounds. AlgiMed(TM) is a wound dressing intended for use on moderate to heavily exudating wounds. Alginate is a natural polymer derived from seaweed, which promotes healing by absorbing excess fluid, controlling bleeding and forming a gel, which keeps the tissue surface moist, thus reducing scarring. Since AlgiMed donates calcium ions to the wound site, it promotes coagulation and therefore hemostasis. The total market for moist wound healing dressings (composed of hydrogels, alginates, hydrocolloids, foams and films) is estimated at $1.3 billion annually on a worldwide basis. Of that total market, hydrogel and alginate dressings represent about $600 million annually. We believe the advanced wound management market is growing in the 7%-9% range annually. Over the last 40 years, the moist wound therapy concept has been a major advance in wound treatment. Chronic wounds such as diabetic foot ulcers pose particular treatment challenges, and a moist wound healing environment can contribute significantly to meeting this challenge. Reduced healing times for diabetic foot ulcers lower the cost of management and the risk of further complications such as amputation. Current revenue sources for CardioTech include patented medical grade polyurethanes for use in implantable medical devices, disposable devices manufactured on an OEM basis for certain Fortune 100 companies, cardiovascular tubing systems, arterial filters, oxygenators, cardioplegia delivery systems and oxygen saturation monitors. CardioTech is also developing a synthetic coronary artery bypass graft that addresses a potential market of $1.5 billion annually. CardioTech believes that this release contains forward-looking statements that are subject to risks and uncertainties. Such statements are based on management's current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review CardioTech's filings with the Securities and Exchange Commission. For more information please contact: Dave Gentry Aurelius Consulting Group, Inc. (407) 644-4256 info@aureliusconsulting.com www.runonideas.com SOURCE CardioTech International, Inc.